EUVIMEDEUVIMED entdecken
Crossref

Dendritic Polymer‐Based Nanomedicines Remodel the Tumor Stroma: Improve Drug Penetration and Enhance Antitumor Immune Response

Yuxin Zhang, Zaixiang Fang, Dayi Pan, Yunkun Li, Jie Zhou, Hongying Chen, Zhiqian Li, Mengli Zhu, Cong Li, Liwen Qin, Xiangyi Ren, Qiyong Gong und 1 weitere

Advanced Materials · 2024-06 · 36 (25)

DOI: 10.1002/adma.202401304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 22.03.2024. Verfasst von Yuxin Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Huaxi MR Research Center (HMRRC), Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Bi…. Hauptthemen laut MEDLINE: Nanomedicine, Antineoplastic Agents. Die Arbeit wurde bisher 116-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The dense extracellular matrix (ECM) in solid tumors, contributed by cancer‐associated fibroblasts (CAFs), hinders penetration of drugs and diminishes their therapeutic outcomes. A sequential treatment strategy of remodeling the ECM via a CAF modifier (dasatinib, DAS) is proposed to promote penetration of an immunogenic cell death (ICD) inducer (epirubicin, Epi) via apoptotic vesicles, ultimately enhancing the treatment efficacy against breast cancer. Dendritic poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA)‐based nanomedicines (poly[OEGMA‐Dendron(G2)‐Gly‐Phe‐Leu‐Gly‐DAS] (P‐DAS) and poly[OEGMA‐Dendron(G2)‐hydrazone‐Epi] (P‐Epi)) are developed for sequential delivery of DAS and Epi, respectively. P‐DAS reprograms CAFs to reduce collagen by downregulating collagen anabolism and energy metabolism, thereby reducing the ECM deposition. The regulated ECM can enhance tumor penetration of P‐Epi to strengthen its ICD effect, leading to an amplified antitumor immune response. In breast cancer‐bearing mice, this approach alleviates the ECM barrier, resulting in reduced tumor burden and increased cytotoxic T lymphocyte infiltration, and more encouragingly, synergizes effectively with anti‐programmed cell death 1 (PD‐1) therapy, significantly inhibiting tumor growth and preventing lung metastasis. Furthermore, systemic toxicity is barely detectable after sequential treatment with P‐DAS and P‐Epi. This approach opens a new avenue for treating desmoplastic tumors by metabolically targeting CAFs to overcome the ECM barrier.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanomedicineAntineoplastic AgentsAnimalsMiceHumansCell Line, TumorDendrimersFemaleExtracellular MatrixBreast NeoplasmsCancer-Associated FibroblastsDrug Carriers

Stichwörter der Autor:innen

ECM regulationantitumor immune responsecancer‐associated fibroblastsdendritic polymer‐based nanomedicinesdrug penetration

Substanzen

Antineoplastic AgentsDendrimersDrug Carriers

Autor:innen und Institutionen

  • Department of Radiology, Huaxi MR Research Center (HMRRC), Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, Ch…
  • Functional and Molecular Imaging Key Laboratory of Sichuan Province, and Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu, 610041, China.
  • Department of Radiology, West China Xiamen Hospital of Sichuan University, Xiamen, 361021, China.

ORCID-Profile: Kui Luo

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
  • Post-Doctor Research Project, West China Hospital, Sichuan University
  • National Science and Technology Major Project
  • Science and Technology Department of Sichuan Province

Zitieren

APA

Zhang, Y., Fang, Z., Pan, D., Li, Y., Zhou, J., Chen, H., Li, Z., Zhu, M., Li, C., Qin, L., Ren, X., Gong, Q., & Luo, K. (2024). Dendritic Polymer‐Based Nanomedicines Remodel the Tumor Stroma: Improve Drug Penetration and Enhance Antitumor Immune Response. Advanced Materials, 36(25). https://doi.org/10.1002/adma.202401304

Vancouver

Zhang Y, Fang Z, Pan D, Li Y, Zhou J, Chen H, et al. Dendritic Polymer‐Based Nanomedicines Remodel the Tumor Stroma: Improve Drug Penetration and Enhance Antitumor Immune Response. Advanced Materials. 2024;36(25). doi:10.1002/adma.202401304

BibTeX
@article{Zhang2024,
  author = {Zhang, Yuxin and Fang, Zaixiang and Pan, Dayi and Li, Yunkun and Zhou, Jie and Chen, Hongying and Li, Zhiqian and Zhu, Mengli and Li, Cong and Qin, Liwen and Ren, Xiangyi and Gong, Qiyong and Luo, Kui},
  title = {Dendritic Polymer‐Based Nanomedicines Remodel the Tumor Stroma: Improve Drug Penetration and Enhance Antitumor Immune Response},
  journal = {Advanced Materials},
  year = {2024},
  volume = {36},
  number = {25},
  doi = {10.1002/adma.202401304}
}
Kostenlos starten →